From: Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
Life years
Quality-adjusted life years
Years since initiation
PSM and Dabi
PCpc and Hpc and Hvp
1
0.90
0.88
0.56
0.54
5
3.77
3.55
2.21
2.06
10
6.09
5.51
3.43
3.10
Lifetime
8.45
7.29
4.59
3.99